PET/CT Imaging with 124I-PU-AD in Patients with Solid Tumors, Plasma Cell Myeloma, Lymphoma, or Alzheimer's Disease

Inclusion Criteria

• Negative serum pregnancy test for females of childbearing age (11-50 years) and/or lack child-bearing potential
• No breast-feeding
• Patients with a diagnosis of cancer and/or Alzheimer's disease, meeting trial eligibility criteria
• For cancer patients: * Patients with eligible histologic type of cancer; eligible histologic types of cancer types include solid malignancy, myeloma, and lymphoma * Cancer histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology * Cancerous disease is radiologically-measurable or evaluable as defined by published tumor response criteria (including but not limited to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
• For Alzheimer's disease patients: * Established diagnosis of mild-moderate Alzheimer's disease based upon neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria * Documentation of diagnosis of mild-moderate Alzheimer's disease, as above, by board-certified neurologist (MSKCC or non-MSKCC) * Patient has an appointed health care proxy specifically designated for research consent and that this appointment is documented * Patient has designated at-home caregiver(s) responsible for providing daily medications to the patient, who will document the patient's daily doses of saturating solution of potassium iodide (SSKI) oral medication, for 2 weeks as per study protocol
• For patients who have both cancer and Alzheimer's disease, patients are considered eligible if they meet all eligibility requirements for either Alzheimer's disease of cancer patients

Exclusion Criteria

• Previous allergic reaction to X-ray CT iodinated contrast medium
• Hypersensitivity to iodide products
• Known hyperthyroidism
• Bilirubin > 1.5 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
• Albumin < 2 g/dl
• Gamma-glutamyl transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
• Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min
• Acute major illness (e.g., unstable cardiovascular condition)
• Patient inability to give consent personally or via appointed health care proxy